As previously reported, the Federal Court dismissed Apotex’s application for judicial review of the decision of the Therapeutic Products Directorate (TPD), which continued to require Apotex to submit additional information with respect to products manufactured or tested in Apotex’s facilities in India. On August 2, 2018, the Federal Court of Appeal dismissed Apotex’s appeal: Apotex Inc v Canada (Health), 2018 FCA 147. The Federal Court of Appeal found that the application judge made no reviewable error in finding that the TPD’s decision was not improperly motivated, and dismissed the appeal.
Related Publications & Articles
-
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More -
Federal Court of Appeal dismisses appeal of SPRAVATO “innovative drug” decision
On November 10, 2021, the Minister of Health refused to reassess its decision that Janssen’s esketamine hydrochloride product (SPRAVATO) was not an “innovative drug” and therefore not entitled to data...Read More -
Federal Court finds patent for concentrated methotrexate solutions obvious
On March 26, 2024, the Federal Court dismissed Medexus and Medac’s action for patent infringement of Canadian Patent No 2,659,662, finding the asserted claims invalid for obviousness: Medexus Pharmace...Read More